Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539262 · ClinicalTrials.gov registry record · Phase 1
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
NCT04539262 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 156 participants.
The verdict
NCT04539262, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
Study Summary
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).
Interventions
- DRUG Placebo
- DRUG Remdesivir (RDV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2021-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04539262
The ClinicalTrials.gov registry entry for NCT04539262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04539262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04539262 about?
NCT04539262 is a clinical study titled "Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation". The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04539262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2020-09-14. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT04539262?
The interventions under investigation include: Placebo (DRUG), Remdesivir (RDV) (DRUG).
Who is sponsoring clinical trial NCT04539262?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.